HSA
STOK icon

Hussman Strategic Advisors’s Stoke Therapeutics STOK Stock Holding History

Hussman Strategic Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Sell
42,000
-42,000
-50% -$1.35M 0.32% 150
2026
Q1 		$2.74M Buy
84,000
+21,000
+33% +$689K 0.59% 49
2025
Q4 		$2M Buy
+63,000
New +$1.89M 0.48% 90

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hussman Strategic Advisors's STOK Position: Q2 2026 in Review

Hussman Strategic Advisors reduced its Stoke Therapeutics (STOK) stake by 50% in Q2 2026, selling an estimated $1.35M and leaving 42,000 shares worth $1.37M. The position accounts for 0.32% of the portfolio, ranked #150.

Hussman Strategic Advisors first reported a position in STOK in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.74M in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Hussman Strategic Advisors held 42,000 shares of Stoke Therapeutics worth $1.37M as of Q2 2026.
  • Hussman Strategic Advisors sold 42,000 Stoke Therapeutics shares in Q2 2026, an estimated $1.35M.
  • Stoke Therapeutics made up 0.32% of Hussman Strategic Advisors's portfolio in Q2 2026, its #150 holding.
  • Hussman Strategic Advisors first reported a position in Stoke Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Hussman Strategic Advisors's Stoke Therapeutics position peaked at $2.74M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.